

**QUALIFICATION CERTIFICATE
PURSUANT TO NATIONAL INSTRUMENT 44-101**

TO: British Columbia Securities Commission
Ontario Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Newfoundland and Labrador Securities Commission
Nova Scotia Securities Commission
Prince Edward Island Securities Office

**RE: MYDECINE INNOVATIONS GROUP INC.
Preliminary Short Form Prospectus dated January 20, 2021**

The undersigned, being one of the executive officers of Mydecine Innovations Group Inc. (the "**Company**"), hereby certifies on behalf of the Company, pursuant to section 4.1(a)(ii) of National Instrument 44-101 *Short Form Prospectus Distributions* ("**NI 44-101**"), that as at the date of this certificate:

- (i) the Company is relying on section 2.2 of NI 44-101 in order to be qualified to file a prospectus in the form of a short form prospectus;
- (ii) all of the qualification criteria set forth in section 2.2 of NI 44-101 have been satisfied; and
- (iii) all of the material incorporated by reference in the preliminary short form base shelf prospectus and not previously filed is being filed with the preliminary short form base shelf prospectus.

DATED: January 20, 2021

MYDECINE INNOVATIONS GROUP INC.

(Signed) "David Joshua Bartch"
David Joshua Bartch
Chief Executive Officer